Jupiter Neurosciences (JUNS) said Monday that it signed an agreement with Catalent Pharma Solutions for the production of Jotrol softgel capsules for Jupiter's upcoming phase 2a clinical trial in Parkinson's disease.

Jotrol is Jupiter's oral formulation of resveratrol and under the deal, Catalent will manufacture clinical batches of Jotrol using a softgel formulation, according to the statement. No financial details were disclosed.

Jupiter said the production will include active and placebo batches for its planned Parkinson's study, which will evaluate Jotrol's safety, tolerability, and pharmacokinetics in patients with Parkinson's disease over a three-month period.

Shares of Jupiter Neurosciences were down more than 9% in recent Monday trading.

Price: 0.93, Change: -0.10, Percent Change: -9.32